

**To:** [redacted] [redacted]@astrazeneca.com  
**Cc:** [redacted] [redacted]@astrazeneca.com; [redacted] [redacted]@minvws.nl; [redacted] [redacted]@minvws.nl; [redacted] [redacted]@minvws.nl; [redacted] [redacted]@minvws.nl  
**From:** [redacted]  
**Sent:** Fri 12/18/2020 3:27:11 PM  
**Subject:** expression of interest  
**Received:** Fri 12/18/2020 3:27:11 PM

Dear Ms. [redacted]

Thank you for yesterday's meeting. This is just to confirm our interest in an possible advance purchase agreement early 2021 regarding a volume of [redacted] AZD7442.

Any final decision from our side for such an agreement is pending on further considerations regarding among other things our medical need, the competitive market landscape, price and transparency and the feasibility and desirability of alternative regulatory early access routes.

With best regards,

[redacted]  
Ministry of Health

